Wolverine Trading’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $676M | Buy |
929,900
+211,800
| +29% | +$158M | 0.49% | 37 |
|
|
2025
Q2 | $557M | Buy |
718,100
+89,900
| +14% | +$69.9M | 0.56% | 31 |
|
|
2025
Q1 | $517M | Buy |
628,200
+220,000
| +54% | +$183M | 0.6% | 32 |
|
|
2024
Q4 | $316M | Sell |
408,200
-23,300
| -5% | -$19.3M | 0.3% | 42 |
|
|
2024
Q3 | $379M | Sell |
431,500
-31,800
| -7% | -$28.6M | 0.4% | 38 |
|
|
2024
Q2 | $419M | Buy |
463,300
+215,000
| +87% | +$172M | 0.44% | 29 |
|
|
2024
Q1 | $193M | Sell |
248,300
-8,400
| -3% | -$5.98M | 0.2% | 56 |
|
|
2023
Q4 | $150M | Sell |
256,700
-9,100
| -3% | -$5.31M | 0.16% | 65 |
|
|
2023
Q3 | $143M | Sell |
265,800
-29,000
| -10% | -$14.9M | 0.15% | 66 |
|
|
2023
Q2 | $137M | Buy |
294,800
+7,300
| +3% | +$3.06M | 0.17% | 61 |
|
|
2023
Q1 | $97.9M | Buy |
287,500
+19,900
| +7% | +$6.71M | 0.15% | 69 |
|
|
2022
Q4 | $97.9M | Buy |
+267,600
| New | +$94.9M | 0.15% | 98 |
|
|
2022
Q3 | – | Sell |
-137,500
| Closed | -$44.4M | – | 5007 |
|
|
2022
Q2 | $44.4M | Buy |
137,500
+72,100
| +110% | +$21.6M | 0.07% | 140 |
|
|
2022
Q1 | $19M | Sell |
65,400
-77,100
| -54% | -$19.8M | 0.02% | 449 |
|
|
2021
Q4 | $39.5M | Buy |
142,500
+12,300
| +9% | +$3.12M | 0.05% | 280 |
|
|
2021
Q3 | $30M | Sell |
130,200
-4,500
| -3% | -$1.11M | 0.03% | 382 |
|
|
2021
Q2 | $30.9M | Buy |
134,700
+25,900
| +24% | +$5.2M | 0.05% | 283 |
|
|
2021
Q1 | $20.2M | Buy |
108,800
+24,700
| +29% | +$4.83M | 0.03% | 397 |
|
|
2020
Q4 | $14M | Sell |
84,100
-12,300
| -13% | -$1.84M | 0.02% | 518 |
|
|
2020
Q3 | $14.1M | Sell |
96,400
-30,300
| -24% | -$4.69M | 0.03% | 407 |
|
|
2020
Q2 | $20.6M | Buy |
126,700
+16,000
| +14% | +$2.46M | 0.06% | 242 |
|
|
2020
Q1 | $15.3M | Sell |
110,700
-134,300
| -55% | -$18.5M | 0.05% | 301 |
|
|
2019
Q4 | $32.2M | Buy |
245,000
+79,800
| +48% | +$9.25M | 0.08% | 198 |
|
|
2019
Q3 | $18.6M | Sell |
165,200
-77,600
| -32% | -$8.64M | 0.05% | 298 |
|
|
2019
Q2 | $26.9M | Sell |
242,800
-22,700
| -9% | -$2.67M | 0.08% | 209 |
|
|
2019
Q1 | $34.5M | Buy |
265,500
+31,200
| +13% | +$3.79M | 0.1% | 153 |
|
|
2018
Q4 | $26.8M | Buy |
234,300
+8,000
| +4% | +$894K | 0.08% | 180 |
|
|
2018
Q3 | $24.3M | Buy |
226,300
+144,100
| +175% | +$14.4M | 0.05% | 249 |
|
|
2018
Q2 | $6.36M | Hold |
82,200
| – | – | 0.02% | 718 |
|
|
2018
Q1 | $6.36M | Buy |
82,200
+23,300
| +40% | +$1.88M | 0.02% | 718 |
|
|
2017
Q4 | $4.97M | Buy |
+58,900
| New | +$5.01M | 0.02% | 865 |
|
|
2017
Q3 | – | Sell |
-108,700
| Closed | -$8.99M | – | 4760 |
|
|
2017
Q2 | $8.99M | Buy |
108,700
+6,500
| +6% | +$530K | 0.04% | 407 |
|
|
2017
Q1 | $8.66M | Sell |
102,200
-157,700
| -61% | -$12.6M | 0.05% | 402 |
|
|
2016
Q4 | $19.1M | Buy |
259,900
+3,500
| +1% | +$261K | 0.09% | 219 |
|
|
2016
Q3 | $20.4M | Buy |
256,400
+108,400
| +73% | +$8.68M | 0.1% | 218 |
|
|
2016
Q2 | $11.6M | Buy |
+148,000
| New | +$11.1M | 0.07% | 311 |
|
Other funds holding LLY
Wolverine Trading's LLY Position: Q3 2025 in Review
Wolverine Trading reduced its Eli Lilly (LLY) stake by 51% in Q3 2025, selling an estimated $15.2M and leaving 19,630 shares worth $14.3M. The position accounts for 0.01% of the portfolio, ranked #750.
Wolverine Trading first reported a position in LLY in Q2 2016 and has held it in 35 quarters since. The position peaked at $147M in Q2 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.
- Wolverine Trading held 19,630 shares of Eli Lilly worth $14.3M as of Q3 2025.
- Wolverine Trading sold 20,386 Eli Lilly shares in Q3 2025, an estimated $15.2M.
- Eli Lilly made up 0.01% of Wolverine Trading's portfolio in Q3 2025, its #750 holding.
- Wolverine Trading first reported a position in Eli Lilly in Q2 2016 and has held it in 35 quarters since.
- Wolverine Trading's Eli Lilly position peaked at $147M in Q2 2024.
- 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.